Physiological variables and molecular study of KLK2 and KLK3 among patient with benign prostatic hyperplasia
This study includes 60 patients with prostatic hyperplasia with an average age of 64 years old and 30 samples as a control with same age group. The study obtained that there was significant association (P ≤ 0.05) between PSA (KLK3) and prostatic hyperplasia. Result also mentions that there was significant decrease in testosterone level and significant increase in dihydrotestosterone level. The present study for KLK2 and KLK3 genes showed molecular variation in both genes, varied between polymorphism and allele polymorphism. PCR amplification of specific primers of KLK2 gene showed polymorphisms ranged between 14%, 8%, 10%, and 6% in each KLK2a, KLK2b, KLK2c, and KLK2d primers respectively, while the allele polymorphism in KLK2c amplification with primer reaches 18% of patient. PCR amplification of specific primers of KLK3 gene showed polymorphisms ranged between 10%, 6%, 2%, and 4% in each KLK3a, KLK3b, KLK3c, and KLK3d primer respectively, and allele variation was not detected in amplification product of KLK3.
Several nonmalignant histological prostate findings have been shown to be of clinical relevance. For example, we and others have shown chronic histological prostate inflammation in needle biopsies is associated with worsening prostatitis- and benign prostate hyperplasia (BPH)-related symptoms over time.1,2 While basal cell hyperplasia (BCH) in the transitional zone has been associated with BPH in prior studies, the clinical significance of BCH in needle biopsies of the peripheral zone has not been previously studied in earnest.
Conclusion: In conclusion, our study indicates a negative association between CYP17 and BPH in Orientals.
In this study, interventions for BPH reached cost equivalence with combination medical therapy within 6 months to 8 years.SummaryA myriad of options for managing men with symptomatic BPH exist. It is prudent not only to consider surgeon preference and patient-specific factors when selecting a treatment but also to understand the economic impact different BPH therapies confer.
ENGINEERING Correction for “Computer simulations suggest that prostate enlargement due to benign prostatic hyperplasia mechanically impedes prostate cancer growth,” by Guillermo Lorenzo, Thomas J. R. Hughes, Pablo Dominguez-Frojan, Alessandro Reali, and Hector Gomez, which was first published January 7, 2019; 10.1073/pnas.1815735116 (Proc. Natl. Acad. Sci. U.S.A. 116, 1152–1161). The authors...
Conclusions: In the model of BPH induced by testosterone propionate after castration, KQR can inhibit the conduction of the TGF-β/Smad signaling pathway by upregulating the expression of BAMBI protein and reversing EMT in rat prostate tissue. PMID: 31186664 [PubMed]
Conclusions: Elevated SA level is an independent predictor of prostate cancer as well as its bone metastases. Therefore, SA level may be a promising diagnostic and prognostic biomarker for prostate cancer and bone metastases.
4-1BB ligand (4-1BBL) was a transmembrane glycoprotein belonging to the tumor necrosis factor family. It was expressed on activated T lymphocytes and function as a co-stimulatory molecule via cross-linking with 4-1BB (a.k.a, CD137). In addition to its role in immune regulation, 4-1BBL transmitted signals into the cells on which it was expressed (reverse signaling). 4-1BBL represented a promising target for enhancing antitumor immune responses. Recent studies indicated that 4-1BBL also expressed in non-immune cells and possessed different functions in various types of cells. Here, we reported that 4-1BBL didn't express in n...
PMID: 31195369 [PubMed - as supplied by publisher]
We present our experiences with this technique, which can be quickly performed under local anesthesia in an office setting. PMID: 31180311 [PubMed - in process]